2018
Antibody Persistence at the Population Level 5 Years After Mass Vaccination With Meningococcal Serogroup A Conjugate Vaccine (PsA-TT) in Burkina Faso: Need for a Booster Campaign?
Yaro S, Lafourcade B, Ouangraoua S, Ouoba A, Kpoda H, Findlow H, Tall H, Seanehia J, Martin C, Ouedraogo J, Gessner B, Meda N, Borrow R, Trotter C, Mueller J. Antibody Persistence at the Population Level 5 Years After Mass Vaccination With Meningococcal Serogroup A Conjugate Vaccine (PsA-TT) in Burkina Faso: Need for a Booster Campaign? Clinical Infectious Diseases 2018, 68: 435-443. PMID: 30481265, DOI: 10.1093/cid/ciy488.Peer-Reviewed Original ResearchConceptsPre-vaccination levelsAge groupsBooster campaignAntibody persistenceMeningococcal serogroup A conjugate vaccineSerum bactericidal antibody titersBactericidal antibody titersYounger age groupsOlder age groupsImmunoglobulin G concentrationCross-sectional surveyTime of returnDifferent age groupsConjugate vaccineAntibody titersImmune protectionGeneral populationMass vaccinationSerological surveyComplete returnOlder individualsMass campaignsBurkina FasoGeometric meanBobo-Dioulasso
2013
Rubella seroprevalence among pregnant women in Burkina Faso
Tahita M, Hübschen J, Tarnagda Z, Ernest D, Charpentier E, Kremer J, Muller C, Ouedraogo J. Rubella seroprevalence among pregnant women in Burkina Faso. BMC Infectious Diseases 2013, 13: 164. PMID: 23556510, PMCID: PMC3623657, DOI: 10.1186/1471-2334-13-164.Peer-Reviewed Original ResearchConceptsOverall seropositivity ratePregnant womenRubella seroprevalenceSeropositivity rateNon-immune pregnant womenRubella-specific IgG antibodiesOverall immunity rateOlder age groupsRubella infectionEarly pregnancyAntibody titersRoutine immunizationCommercial ELISA kitIgG antibodiesImmunity rateRubella virusAge groupsELISA kitSerum samplesBurkina FasoWomenInternational unitsSeroprevalenceHigh percentageSerious consequences